Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

CNBC's Karen Gilchrist weighs in on Zealand Pharma's "next generation" obesity drug candidate and its search for a global ...

Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...

Zealand Pharma is working on the next-gen weight-loss treatment. Its Petrelintide showed promising results in a Phase 1b ...

Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s ...

No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug ...

The regulator sought additional analyses from existing continuous glucose monitoring data collected during Phase III trials.

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application ...

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) traded down 2.3% during trading on Wednesday . The stock traded as low as $115.00 and last traded at $115.00. 505 shares traded hands during ...

Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease ...

After third-party manufacturing issues led to a December rejection of Zealand Pharma’s pediatric congenital hyperinsulinism (CHI) candidate, the Danish pharma’s latest snub seems to come down to ti | ...

Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III ...